<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804829</url>
  </required_header>
  <id_info>
    <org_study_id>988</org_study_id>
    <nct_id>NCT01804829</nct_id>
  </id_info>
  <brief_title>Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.</brief_title>
  <official_title>A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotest Pharmaceuticals Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of Civacir® to prevent the
      recurrence of Hepatitis C Virus (HCV) after liver transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Civacir® 10%, Hepatitis C Immune Globulin Intravenous (Human) is a high-titer human
      polyclonal immune globulin (IgG) containing a diversity of antibodies that target and bind
      the hepatitis C virus (HCV) to prevent infection. Subjects who reduce their viral load to
      less than 100 IU/ml HCV RNA through up to 16 weeks of antiviral therapy prior to liver
      transplant are enrolled in the study. There is no requirement to reach undetectable virus
      prior to transplant as the function of Civacir® is to neutralize any remaining virus in
      circulation.

      Subjects randomized to Civacir® treatment arms receive study drug infusions starting on the
      day of liver transplant followed by 15 doses over a 10 week period to prevent the recurrence
      of quantifiable Hepatitis C Virus (HCV) after liver transplant. The study will evaluate
      dosing arms ranging from 200 mg/kg to 400 mg/kg compared to a control arm. For the primary
      endpoint, efficacy is defined as persistent viral load suppression maintaining HCV RNA
      levels below the lower limit of quantitation as determined by central laboratory Polymerase
      Chain Reaction (PCR) at 12 weeks post-liver transplant and then at 24 weeks post-liver
      transplant to demonstrate durability of effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Determine the efficacy of Civacir® in preventing post-transplant HCV recurrence at 12 weeks post transplant</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to assess the effect of administering Civacir® anti-HCV immunoglobulin therapy on prevention of orthotopic liver transplant (OLT) HCV recurrence, as measured by the proportion of subjects with unquantifiable HCV RNA levels at 12 weeks post-OLT, compared to the control group (not treated with Civacir® and considered standard of care).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the efficacy of Civacir® in preventing post-transplant HCV recurrence at 4 and 24 weeks post transplant</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the proportion of subjects with unquantifiable HCV RNA, as measured quantitatively by PCR at 4 and 24 weeks post-OLT, for assessing the durability of effect.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the biochemical response of Civacir® in preventing post-transplant HCV recurrence at 12 and 24 weeks post transplant</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the biochemical response at 12 and 24 weeks post-transplant: the proportions of subjects with normal ALT, AST, total bilirubin and alkaline phosphates at 12 and 24 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the safety of Civacir® in preventing post-transplant HCV recurrence up to 24 weeks post transplant</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the safety of Civacir® in the treatment of subjects with HCV undergoing liver transplantation by the number of adverse events including safety laboratory parameters.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the pharmacokinetics of Civacir® up to 24 weeks post transplant</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the pharmacokinetics of Civacir® following intravenous infusion(s).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatitis C Infection</condition>
  <condition>Viruses</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Observational Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects who attain HCV RNA &lt;100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 24 week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Civacir® 10% at 200 mg/kg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who attain HCV RNA &lt;100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 24 weeks post-transplant.
If sufficient efficacy is not demonstrated at 200 mg/kg, then this arm would be replaced by a 400 mg/kg arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Civacir® 10% at 300 mg/kg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who attain HCV RNA &lt;100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 24 weeks post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Civacir® 10%</intervention_name>
    <description>The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.</description>
    <arm_group_label>Civacir® 10% at 200 mg/kg dose</arm_group_label>
    <arm_group_label>Civacir® 10% at 300 mg/kg dose</arm_group_label>
    <other_name>Civacir®</other_name>
    <other_name>Hepatitis C Immune Globulin Intravenous (Human)</other_name>
    <other_name>human polyclonal immune globulin (IgG)</other_name>
    <other_name>HCIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained up to 4 months prior to orthotopic liver
             transplantation (OLT) and reconsent every 3 months

          -  HCV Genotype 1 Infection.

          -  Subjects treated with antiviral therapy for up to and including 16 weeks prior to
             OLT.

          -  Most recent evidence within the last 4 weeks that HCV RNA is &lt;100 IU/mL.

          -  Male and female subjects (age 18-70 years).

          -  Subject weight under 250 pounds.

          -  Stable patient in a condition which in the opinion of the investigator would permit
             safe participation in the study.

        Exclusion Criteria:

          -  Re-transplantation due to viral recurrence.

          -  Positive HIV or Hepatitis B Virus (HBV) test at time of transplantation.

          -  Most recent PCR test indicating HCV RNA ≥100 IU/mL within 4 weeks of OLT.

          -  Subjects having received organs from HCV positive donors.

          -  Serum creatinine level &gt;2.5 times the upper limit of normal or advanced renal disease
             at screening.

          -  Pregnancy or single contraceptive measure or lactation period (females only).

          -  Known intolerance to immunoglobulins or comparable substances (e.g. vaccination
             reaction).

          -  Known absolute Immunoglobulin A (IgA) deficiency.

          -  Known intolerance to proteins of human origin.

          -  Participation in another clinical trial within 90 days before signing Informed
             Consent Form (ICF) or during the study, and/or previous participation in this study
             (except for Study 988 screen failures).

          -  Active drug and/or alcohol abuse.

          -  Inability or lacking motivation to participate in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norah Terrault, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Osgood</last_name>
    <phone>561-989-5813</phone>
    <email>gosgood@biotestpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Dougherty, PhD, MS</last_name>
    <phone>561-989-5754</phone>
    <email>cdougherty@biotestpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keck School of Medicine of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Linda Sher, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norah Terrault, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kaylan Bhamidimarri, M.D., MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Transplant Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hicham Khallafi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roshan Shrestha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Rosenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Therapondos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas D Schiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth Verna, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lewis Teperman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, St. Lukes Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John M Vierling, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norman L Sussman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Campsen, M.D., FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel G Maluf, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biotestpharma.com/index.php?src=gendocs&amp;ref=HepatitisCImmuneGlobulin&amp;category=Pipeline</url>
    <description>Biotest Pharmaceuticals Hepatitis C Immune Globulin (HCIG)</description>
  </link>
  <reference>
    <citation>Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013 May;57(5):1752-62. doi: 10.1002/hep.25976. Epub 2013 Jan 17.</citation>
    <PMID>22821361</PMID>
  </reference>
  <reference>
    <citation>Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW Jr; Collaborative Antiviral Study Group. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005 Aug;11(8):941-9.</citation>
    <PMID>16035063</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 21, 2013</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV Liver Transplant Immunoglobulin PCR SVR</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
